In our previous study, we found that disrupting TOPBP1-PHF8 interaction suppresses breast tumorigenesis and creates a breast tumor–specific susceptibility to PARP inhibitor rucaparib and platinum drug cisplatin (34). Here, PHF8 is linked to breast neoplasm.